Literature DB >> 1615101

Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.

T P Hogan1, A G Awad.   

Abstract

The schizophrenic patient's early psychological response to neuroleptic treatment has been demonstrated to be a significant predictor of treatment response. The validity of the construct of subjective response is evaluated by comparison of two measures. Fifty-five recently admitted and unmedicated schizophrenic patients were randomly allocated to chlorpromazine or haloperidol. Subjective responses at 24 and 48 hours as assessed by two different scales, the Van Putten & May scale and the self-administered Drug Attitude Inventory, were strongly correlated with outcome at three weeks. Early emergence of extrapyramidal symptoms was not related to subjective response, but dysphoric patients had a greater incidence of EPS by the end of treatment than did non-dysphoric patients. The two measures showed high concordance in identification of early drug dysphoria.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615101     DOI: 10.1017/s0033291700030282

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  32 in total

1.  [The initial dysphoric reaction (IDR) to the first dose of neuroleptics].

Authors:  B Graf Schimmelmann; M Schacht; C Perro; M Lambert
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 2.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

Review 3.  Methodological issues in current antipsychotic drug trials.

Authors:  Stefan Leucht; Stephan Heres; Johannes Hamann; John M Kane
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

4.  Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability.

Authors:  Sourabh Moti Singh; Peter M Haddad; Nusrat Husain; Eamonn Heaney; Barbara Tomenson; Imran B Chaudhry
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

5.  Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing.

Authors:  Naoaki Kuroda; Shiyou Sun; Chih-Kuang Lin; Nobuaki Morita; Hirotaka Kashiwase; Fude Yang; Yoji Nakatani
Journal:  Environ Health Prev Med       Date:  2008-08-12       Impact factor: 3.674

6.  The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale.

Authors:  Hikaru Hori; Nobuhisa Ueda; Hideki Shiozuka; Ryohei Igata; Tazuko Miki; Kiyokazu Atake; Yuji Takeuchi; Hiroaki Shirozu; Naotoshi Ohara; Yuki Konishi; Hiroshi Nagai; Noriaki Sakurai; Takanori Kubota; Reiji Yoshimura
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-06

Review 7.  Measuring quality of life in patients with schizophrenia: an update.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

8.  Risk factors for non-adherence to antidepressant treatment in patients with mood disorders.

Authors:  Carlos De las Cuevas; Wenceslao Peñate; Emilio J Sanz
Journal:  Eur J Clin Pharmacol       Date:  2013-09-08       Impact factor: 2.953

Review 9.  Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.

Authors:  Hanjing Emily Wu; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2015-06

Review 10.  Quality-of-Life measurements for patients taking which drugs? The clinical PCASEE perspective.

Authors:  P Bech
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.